Study identification

EU PAS number

EUPAS22012

Study ID

36552

Official title and acronym

CONTOUR Australia: Condition of Submental Fullness and Treatment

DARWIN EU® study

No

Study countries

Australia

Study description

The primary objective of this registry is to develop a comprehensive understanding of how Belkyra is utilized in clinical practice in Australia, following its approval for the treatment of submental fullness due to submental fat, in order to further inform assessment of the risks and benefits associated with its treatment.

Study status

Finalised
Research institutions and networks

Institutions

Parexel International
United States
First published:
10/12/2024
Institution Non-Pharmaceutical company ENCePP partner
Multiple centres: 6 centres are involved in the study

Contact details

Suzanne St Rose

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Allergan
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only